NEW YORK (AP) — Shares of drug developer BIND Therapeutics fell in its first day of trading on the Nasdaq.
The stock dropped 91 cents, or 6.1 percent, to close at $14.09 Friday after raising $70.5 million in an initial public offering of stock.
BIND Therapeutics Inc. priced the offering of 4.7 million shares at $15 each, in the middle of the expected range.
BIND Therapeutics has no products on the market. Its most advanced treatment candidate, BIND-014, is in mid-stage clinical development as a possible treatment for a form of lung cancer and an advanced form of prostate cancer. The company plans to use the offering's proceeds in part to fund BIND-014 development.
The Cambridge, Mass., company trades under the "BIND" ticker symbol.
Wife of US Pastor Held in Iran: 'I Never Thought I’d Have to Battle My Own Gov't For My Husband’s Freedom' | Leah Barkoukis
Politifact: On Second Thought, Obama's 'Keep Your Plan' Pledge is 2013's 'Lie of the Year' | Guy Benson
Conservatives Clash as House Prepares to Vote on Ryan-Murray Budget Deal -- UPDATE: House passes 332-94 | Guy Benson
New White House Push: Sign Up For Obamacare Because It Will Give Your Mother "Piece of Mind" | Daniel Doherty
Heartbreaking: Dad Gives Up Trying to Obtain Health Insurance For His Ailing Son on the Exchanges | Daniel Doherty